U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia BPRNewsWire • 11/22/22
Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022PRNewsWire • 11/02/22
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine TechnologyPRNewsWire • 11/01/22
Approval of extension of exemptions from SIX disclosure and publicity obligationsBusiness Wire • 10/20/22
CSL Plasma Expands in California with New Donation Centers to Collect Life-Saving PlasmaPRNewsWire • 10/11/22
CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic VaccinePRNewsWire • 10/06/22
CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine CandidatesPRNewsWire • 10/05/22
New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health SystemsPRNewsWire • 09/26/22
New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination RatesPRNewsWire • 09/26/22
CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XIPRNewsWire • 09/13/22
Tavneos® (avacopan) recommended by England's NICE for the treatment of AAV (GPA/MPA)Business Wire • 08/18/22
CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)PRNewsWire • 08/17/22
CSL Limited (CSLLY) CEO Paul Perreault on Q4 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/17/22
CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection TechnologyPRNewsWire • 08/04/22
Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. SeasonPRNewsWire • 07/11/22
CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and OlderPRNewsWire • 06/22/22